@prefix pubblicazioni: . @prefix unitaDiPersonaleInterno: . @prefix prodotto: . unitaDiPersonaleInterno:MATRICOLA9323 pubblicazioni:autoreCNRDi prodotto:ID13970 . @prefix prodottidellaricerca: . @prefix istituto: . istituto:CDS017 prodottidellaricerca:prodotto prodotto:ID13970 . @prefix modulo: . modulo:ID2659 prodottidellaricerca:prodotto prodotto:ID13970 . @prefix rdf: . @prefix retescientifica: . prodotto:ID13970 rdf:type retescientifica:ProdottoDellaRicerca , prodotto:TIPO1101 . @prefix rdfs: . prodotto:ID13970 rdfs:label "Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study (Articolo in rivista)"@en . @prefix xsd: . prodotto:ID13970 pubblicazioni:anno "2009-01-01T00:00:00+01:00"^^xsd:gYear ; pubblicazioni:doi "10.1200/JCO.2009.22.4865"^^xsd:string . @prefix skos: . prodotto:ID13970 skos:altLabel "
Cilloni D. ; Renneville A. ; Hermitte F. ; Hills R.K. ; Daly S. ; Jovanovic J.V. ; Gottardi E. ; Fava M ; Schnittger S. ; Weiss T. ; Izzo B. ; Nomdedeu, J. ; van der Heijden A. ; van der Reijden B. A. ; Jansen J. H. ; van der Velden V. H. ; Ommen H. ; Preudhomme C. ; Saglio G. ; Grimwade D. (2009)
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
in Journal of clinical oncology; American society of clinical oncology, Alexandria, Va. (Stati Uniti d'America)
"^^rdf:HTML ; pubblicazioni:autori "Cilloni D. ; Renneville A. ; Hermitte F. ; Hills R.K. ; Daly S. ; Jovanovic J.V. ; Gottardi E. ; Fava M ; Schnittger S. ; Weiss T. ; Izzo B. ; Nomdedeu, J. ; van der Heijden A. ; van der Reijden B. A. ; Jansen J. H. ; van der Velden V. H. ; Ommen H. ; Preudhomme C. ; Saglio G. ; Grimwade D."^^xsd:string ; pubblicazioni:paginaInizio "5195"^^xsd:string ; pubblicazioni:paginaFine "5201"^^xsd:string ; pubblicazioni:numeroVolume "27"^^xsd:string . @prefix ns11: . prodotto:ID13970 pubblicazioni:rivista ns11:ID445121 ; pubblicazioni:numeroFascicolo "31"^^xsd:string ; skos:note "PubMe"^^xsd:string , "ISI Web of Science (WOS)"^^xsd:string ; pubblicazioni:affiliazioni "Biological Sciences, University of Turin, Turin; Department of Hematology, University Federico II, Naples, Italy; Department of Hematology, Biology and Pathology Center, university of Lille Medical School; Cancer Research Institute, Jean-Pierre Aubert Research Center, L'Institut National de la Sant\u00E9 et de la Recherche M\u00E9dicale, U-837, Team 3, Lille; Research & Development, Ipsogen, Marseille, France; Department of Haematology, School of Medicine, Cardiff University, Cardiff; Department of Haematology, Manchester\nRoyal Infirmary, Manchester; Department of Medical and Molecular Genetics, King's College London School of Medicine, London, United Kingdom; Munich Leukemia Laboratory, Munich, Germany; Department of Hematology, Hospital de Sant Pau, Barcelona, Spain; Central Hematology Laboratory, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen; Department of Immunology, Erasmus MC University Medical Center, Rotterdam, the Netherlands; Laboratory of immunohematology, Department of Hematology, \u00C5rhus Sygehus, Tage-Hansens Gade, \u00C5rhus University Hospital, \u00C5rhus, Denmark"^^xsd:string ; pubblicazioni:titolo "Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study"^^xsd:string ; prodottidellaricerca:abstract "Purpose \nRisk stratification in acute myeloid leukemia (AML) is currently based on pretreatment characteristics. It remains to be established whether relapse risk can be better predicted through assessment of minimal residual disease (MRD). One proposed marker is the Wilms tumor gene WT1, which is overexpressed in most patients with AML, thus providing a putative target for immunotherapy, although in the absence of a standardized assay, its utility for MRD monitoring remains controversial. \nPatients and Methods \nNine published and in-house real-time quantitative polymerase chain reaction WT1 assays were systematically evaluated within the European LeukemiaNet; the best-performing assay was applied to diagnostic AML samples (n = 620), follow-up samples from 129 patients treated with intensive combination chemotherapy, and 204 normal peripheral blood (PB) and bone marrow (BM) controls. \nResults \nConsidering relative levels of expression detected in normal PB and BM, WT1 was sufficiently overexpressed to discriminate >= 2-log reduction in transcripts in 46% and 13% of AML patients, according to the respective follow-up sample source. In this informative group, greater WT1 transcript reduction after induction predicted reduced relapse risk (hazard ratio, 0.54 per log reduction; 95% CI, 0.36 to 0.83; P = .004) that remained significant when adjusted for age, WBC count, and cytogenetics. Failure to reduce WT1 transcripts below the threshold limits defined in normal controls by the end of consolidation also predicted increased relapse risk (P = .004). \nConclusion \nApplication of a standardized WT1 assay provides independent prognostic information in AML, lending support to incorporation of early assessment of MRD to develop more robust risk scores, to enhance risk stratification, and to identify patients who may benefit from allogeneic transplantation."@en . @prefix ns12: . prodotto:ID13970 pubblicazioni:editore ns12:ID12850 ; prodottidellaricerca:prodottoDi modulo:ID2659 , istituto:CDS017 ; pubblicazioni:autoreCNR unitaDiPersonaleInterno:MATRICOLA9323 . ns11:ID445121 pubblicazioni:rivistaDi prodotto:ID13970 . ns12:ID12850 pubblicazioni:editoreDi prodotto:ID13970 .